Compugen Discloses Successful Validation Results For Novel B7/CD28–like Cancer Immunotherapy Target Candidate
October 27, 2014 at 07:06 AM EDT
Compugen Ltd. (NASDAQ: CGEN) today disclosed successful experimental data for CGEN-15027, a Compugen-discovered immune checkpoint ...